Literature DB >> 26210691

Programmed cell death protein 1 expression is an independent prognostic factor in gastric cancer after curative resection.

Shohei Eto1, Kozo Yoshikawa2, Masaaki Nishi1, Jun Higashijima1, Takuya Tokunaga1, Toshihiro Nakao1, Hideya Kashihara1, Chie Takasu1, Takashi Iwata1, Mitsuo Shimada1.   

Abstract

BACKGROUND: Programmed cell death protein 1 (PD-1) and its ligand PD-L1 downregulate T cell activation and are related to immune tolerance. The aim of this study was to clarify the significance of PD-1 and PD-L1 expression and to analyze the relationships among PD-1, PD-L1, and Foxp3 expression in gastric cancer.
METHODS: A total of 105 patients who underwent curative gastrectomy for stage II/III gastric cancer were included in this study. PD-1, PD-L1, and Foxp3 expression were examined by immunohistochemistry and related to prognostic factors by univariate and multivariate analyses.
RESULTS: PD-1 expression was correlated with both PD-L1 and Foxp3 expression. Disease-free survival (DFS) was significantly poorer in PD-1-positive patients than in PD-1-negative patients (3-year DFS, 36.1 % vs. 64.7 %, respectively; p < 0.05). Overall survival also tended to be poorer in PD-L1-positive patients than in PD-L1-negative patients. Univariate analysis identified sex, T factor, lymphatic invasion, and PD-1 positivity as significant predictors of poor DFS. Multivariate analysis confirmed male sex, lymphatic invasion, and positive PD-1 expression as independent prognostic indicators.
CONCLUSIONS: PD-1 expression is associated with a poor prognosis and is correlated with PD-L1 and Foxp3 expression in patients with gastric cancer.

Entities:  

Keywords:  Gastric cancer; Programmed cell death 1; Programmed cell death ligand 1

Mesh:

Substances:

Year:  2015        PMID: 26210691     DOI: 10.1007/s10120-015-0519-7

Source DB:  PubMed          Journal:  Gastric Cancer        ISSN: 1436-3291            Impact factor:   7.370


  24 in total

1.  Japanese classification of gastric carcinoma: 3rd English edition.

Authors: 
Journal:  Gastric Cancer       Date:  2011-06       Impact factor: 7.370

2.  Oestrogen treatment of experimental autoimmune encephalomyelitis requires 17β-oestradiol-receptor-positive B cells that up-regulate PD-1 on CD4+ Foxp3+ regulatory T cells.

Authors:  Sheetal Bodhankar; Arthur A Vandenbark; Halina Offner
Journal:  Immunology       Date:  2012-12       Impact factor: 7.397

3.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

Review 4.  Escape from immunotherapy: possible mechanisms that influence tumor regression/progression.

Authors:  Murrium Ahmad; Robert C Rees; Selman A Ali
Journal:  Cancer Immunol Immunother       Date:  2004-06-10       Impact factor: 6.968

5.  High tissue density of FOXP3+ T cells is associated with clinical outcome in prostate cancer.

Authors:  Anna Flammiger; Lars Weisbach; Hartwig Huland; Pierre Tennstedt; Ronald Simon; Sarah Minner; Carsten Bokemeyer; Guido Sauter; Thorsten Schlomm; Martin Trepel
Journal:  Eur J Cancer       Date:  2012-12-21       Impact factor: 9.162

6.  The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer.

Authors:  S Muenst; S D Soysal; F Gao; E C Obermann; D Oertli; W E Gillanders
Journal:  Breast Cancer Res Treat       Date:  2013-06-12       Impact factor: 4.872

7.  Human hepatocellular carcinoma-infiltrating CD4⁺CD69⁺Foxp3⁻ regulatory T cell suppresses T cell response via membrane-bound TGF-β1.

Authors:  Yanmei Han; Yuan Yang; Zhubo Chen; Zhengping Jiang; Yan Gu; Yanfang Liu; Sheng Xu; Chuan Lin; Zeya Pan; Weiping Zhou; Xuetao Cao
Journal:  J Mol Med (Berl)       Date:  2014-03-26       Impact factor: 4.599

8.  Differential pattern and prognostic significance of CD4+, FOXP3+ and IL-17+ tumor infiltrating lymphocytes in ductal and lobular breast cancers.

Authors:  Raoul Droeser; Inti Zlobec; Ergin Kilic; Uwe Güth; Michael Heberer; Giulio Spagnoli; Daniel Oertli; Coya Tapia
Journal:  BMC Cancer       Date:  2012-04-03       Impact factor: 4.430

9.  Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.

Authors:  Y Ishida; Y Agata; K Shibahara; T Honjo
Journal:  EMBO J       Date:  1992-11       Impact factor: 11.598

10.  Combinatorial PD-1 blockade and CD137 activation has therapeutic efficacy in murine cancer models and synergizes with cisplatin.

Authors:  Huafeng Wei; Likun Zhao; Wei Li; Kexing Fan; Weizhu Qian; Sheng Hou; Hao Wang; Min Dai; Ingegerd Hellstrom; Karl Erik Hellstrom; Yajun Guo
Journal:  PLoS One       Date:  2013-12-19       Impact factor: 3.240

View more
  64 in total

1.  A novel tetravalent bispecific antibody targeting programmed death 1 and tyrosine-protein kinase Met for treatment of gastric cancer.

Authors:  Weihua Hou; Qingyun Yuan; Xingxing Yuan; Yuxiong Wang; Wei Mo; Huijie Wang; Min Yu
Journal:  Invest New Drugs       Date:  2018-12-04       Impact factor: 3.850

2.  Clinicopathological features of 22C3 PD-L1 expression with mismatch repair, Epstein-Barr virus status, and cancer genome alterations in metastatic gastric cancer.

Authors:  Akihito Kawazoe; Kohei Shitara; Yasutoshi Kuboki; Hideaki Bando; Takashi Kojima; Takayuki Yoshino; Atsushi Ohtsu; Atsushi Ochiai; Yosuke Togashi; Hiroyoshi Nishikawa; Toshihiko Doi; Takeshi Kuwata
Journal:  Gastric Cancer       Date:  2018-06-01       Impact factor: 7.370

3.  Expression and clinical significance of PD‑1 in hepatocellular carcinoma tissues detected by a novel mouse anti-human PD‑1 monoclonal antibody.

Authors:  Ziwei Li; Bin Li; Dan Peng; Haiyan Xing; Guanying Wang; Pan Li; Jiming Wang; George Ye; Jianhong Chen
Journal:  Int J Oncol       Date:  2018-04-04       Impact factor: 5.650

4.  Poor prognosis in Epstein-Barr virus-negative gastric cancer with lymphoid stroma is associated with immune phenotype.

Authors:  Charles J Cho; Hyo Jeong Kang; Yeon-Mi Ryu; Young Soo Park; Hui Jeong Jeong; Young-Mi Park; Hyun Lim; Jeong Hoon Lee; Ho June Song; Hwoon-Yong Jung; Sang-Yeob Kim; Seung-Jae Myung
Journal:  Gastric Cancer       Date:  2018-04-07       Impact factor: 7.370

5.  Genetic variations in immunomodulatory pathways to predict survival in patients with locoregional gastric cancer.

Authors:  Y Sunakawa; S Cao; N B Volz; M D Berger; D Yang; A Parekh; W Zhang; S Matsusaka; Y Ning; S Stremitzer; S Stintzing; A Sebio; S Okazaki; T Wakatsuki; M Azuma; M Watanabe; W Koizumi; A H Wu; H-J Lenz
Journal:  Pharmacogenomics J       Date:  2016-05-31       Impact factor: 3.550

6.  Tumor-associated macrophage infiltration is highly associated with PD-L1 expression in gastric adenocarcinoma.

Authors:  Kazuto Harada; Xiaochuan Dong; Jeannelyn S Estrella; Arlene M Correa; Yan Xu; Wayne L Hofstetter; Kazuki Sudo; Hisashi Onodera; Koyu Suzuki; Akihiro Suzuki; Randy L Johnson; Zhenning Wang; Shumei Song; Jaffer A Ajani
Journal:  Gastric Cancer       Date:  2017-08-11       Impact factor: 7.370

7.  Analysis of PD1, PDL1, PDL2 expression and T cells infiltration in 1014 gastric cancer patients.

Authors:  Xiaofang Xing; Jianping Guo; Guangyu Ding; Bo Li; Bin Dong; Qin Feng; Shen Li; Jian Zhang; Xiaomin Ying; Xiaojing Cheng; Ting Guo; Hong Du; Ying Hu; Tao Zhou; Xiaohong Wang; Lin Li; Qingda Li; Meng Xie; Liting Li; Xiangyu Gao; Fei Shan; Ziyu Li; Xianzi Wen; Jiping Wang; Jiafu Ji
Journal:  Oncoimmunology       Date:  2017-12-21       Impact factor: 8.110

8.  Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients.

Authors:  Akihito Kawazoe; Takeshi Kuwata; Yasutoshi Kuboki; Kohei Shitara; Akiko Kawano Nagatsuma; Masaaki Aizawa; Takayuki Yoshino; Toshihiko Doi; Atsushi Ohtsu; Atsushi Ochiai
Journal:  Gastric Cancer       Date:  2016-09-14       Impact factor: 7.370

9.  Scoring systems for PD-L1 expression and their prognostic impact in patients with resectable gastric cancer.

Authors:  Marina Alessandra Pereira; Marcus Fernando Kodama Pertille Ramos; André Roncon Dias; Renan Ribeiro; Leonardo Cardili; Bruno Zilberstein; Ivan Cecconello; Ulysses Ribeiro; Evandro Sobroza de Mello; Tiago Biachi de Castria
Journal:  Virchows Arch       Date:  2020-10-24       Impact factor: 4.064

10.  The prediction of survival of patients with gastric cancer with PD-L1 expression using contrast-enhanced ultrasonography.

Authors:  Lin-Ang Wang; Xi Wei; Qing Li; Lin Chen
Journal:  Tumour Biol       Date:  2015-12-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.